亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

810-P: Role of Glucagon-Like-Peptide-1 Agonists as an Adjunctive Treatment in Adults with Type 1 Diabetes Mellitus and Overweight/Obesity, Retrospective Cohort, Saudi Arabia 2023

医学 糖尿病 2型糖尿病 内科学 利拉鲁肽 超重 内分泌学 二甲双胍 队列 胰岛素 回顾性队列研究 肥胖
作者
KHOLOOD HABEEB,Imad Addin Brema,Mohammed S. Almehthel,ALI ALSHEHRI
出处
期刊:Diabetes [American Diabetes Association]
卷期号:73 (Supplement_1) 被引量:1
标识
DOI:10.2337/db24-810-p
摘要

Introduction & Objective: Diabetes is a major public health problem, in 2021, Diabetes affect 537 million adults, and it is estimated to affect 643 million adults by 2030, associated with 6.7 million adult deaths in 2021(1). The Usefulness of Many non-insulin therapies has been investigated in type-1 diabetes like Metformin, and Sodium-Glucose co-transporter-2 inhibitors. Recent evidence on Semaglutide in early Type-1 diabetes shows a promising effect. The study aimed to determine whether Glucagon-Like Peptide-1 Receptor agonist (GLP-1) added to Insulin in Adults with Type-1 Diabetes Mellitus is effective and safe. Methods: A retrospective cohort was conducted (Jan 2022-Feb 2023) among all adults with Type-1 Diabetes on GLP-1 agonists and overweight/Obesity, attending the Diabetes or Obesity clinic in King Fahad Medical City through an Electronic system records review. Excluding those on other non-insulin Diabetes medications, or obesity interventions. Many variables were evaluated to assess the efficacy and safety: Hga1c, CGM data, Weight, biochemical profile, retinal exam, hypoglycemia, and DKA incidence. Student T test Chi-square and linear mixed modeling were used for statistical analysis. Result: 32 patients on GLP-1 agonists were recruited, with a mean age of 30 years, 87% were on Semaglutide (0.5mg or 1mg), while the rest were on Liraglutide (1.2mg-3mg), Estimated Hga1c reduction was 0.84% after 8 months from baseline, p-value <0.001. TIR improved by 15% p value <0.001. 31% of the patients achieved 5% TBWL and 12.5% achieved 15% TBWL p-value <0.001. A significant reduction in insulin total daily dose was observed more in bolus insulin. No Significant hypoglycemia, Retinopathy, or DKA episodes. Conclusions: GLP-1 agonist as adjunctive therapy to insulin shows a significant Improvement in Glycemic control, weight reduction, and insulin requirement in patients with Type-1 diabetes. Disclosure K. Habeeb: None. I. Brema: None. M. Almehthel: None. A. Alshehri: None.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kevin完成签到 ,获得积分10
2秒前
9秒前
orixero的应助被五岁的哈士奇采纳,获得10
10秒前
11秒前
YuxinChen完成签到 ,获得积分10
17秒前
快乐的稚晴完成签到,获得积分10
23秒前
35秒前
小蘑菇的应助被科研通管家采纳,获得10
35秒前
1分钟前
闪闪雍完成签到,获得积分10
1分钟前
1分钟前
健忘的小萱完成签到,获得积分10
1分钟前
玩命的芸遥完成签到,获得积分10
1分钟前
Andrew发布了新的文献求助10
1分钟前
Andrew完成签到,获得积分10
1分钟前
1分钟前
1分钟前
wanci的应助被五岁的哈士奇采纳,获得10
2分钟前
魔幻雪兰完成签到,获得积分10
2分钟前
奋斗的听露完成签到,获得积分10
2分钟前
霸气的似狮完成签到,获得积分10
3分钟前
听话的秋白完成签到,获得积分10
3分钟前
Hello的应助被YYY采纳,获得10
3分钟前
hupo完成签到,获得积分10
3分钟前
含蓄的雪冥完成签到,获得积分10
3分钟前
3分钟前
高高的仇血完成签到,获得积分10
3分钟前
朴实傲白完成签到 ,获得积分10
3分钟前
4分钟前
欢呼的兰完成签到,获得积分10
4分钟前
4分钟前
MT发布了新的文献求助10
4分钟前
soleil关注了科研通微信公众号
4分钟前
贪玩醉薇完成签到,获得积分10
4分钟前
4分钟前
leoo完成签到,获得积分10
4分钟前
腿腿完成签到,获得积分10
4分钟前
欢呼的馒头完成签到,获得积分10
5分钟前
tigger完成签到 ,获得积分10
5分钟前
zilicai的应助被冷阳采纳,获得10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179920
求助须知:如何正确求助?哪些是违规求助? 9570103
关于积分的说明 21808354
捐赠科研通 7775701
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918